ArticleMedical science monitor : international medical journal of experimental and clinical research2025
Radioactive Iodine Therapy for Pediatric Graves' Hyperthyroidism.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early effects of radioactive iodine (I-131) therapy on liver function in patients with Graves' disease: a 48-h analysis.BMC research notes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND The aim of this study was to determine the remission rate and factors influencing radioactive iodine (RAI) therapy in pediatric patients with Graves' hyperthyroidism (GH) who received treatment for the first time. MATERIAL AND METHODS This retrospective study analyzed a total of 44 pediatric patients with GH who received their first RAI therapy in the nuclear treatment ward of Linyi People's Hospital from December 2018 to December 2023. Follow-up was conducted for 6 months after treatment, and based on treatment outcomes, the patients were divided into the remission group and the failure group. SPSS 22.0 statistical software was used to compare and analyze the predictive factors between the 2 groups. RESULTS The total remission rate of GH at 6 months after RAI therapy was 52.3% (23/44). There were significant differences between the remission group and the failure group in terms of duration of GH, thyroid weight, and RAI dose. Logistic regression analysis indicated that duration of GH and thyroid weight were the factors influencing remission of RAI therapy. Patients with a duration of GH more than 27 months and a thyroid weight greater than 50.17g were less likely to be cured. CONCLUSIONS The disease duration and thyroid weight influenced the RAI therapy outcome in pediatric patients with GH. Higher doses of RAI should be administered to patients with a disease duration exceeding 27 months or thyroid weight surpassing 50.17 g.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.